EMA Management Board – highlights of March 2020 meeting

The European Medicines Agency’s first Management Board meeting of 2020 was held virtually in view of the rapidly changing situation in the context of the COVID-19 pandemic.

The EMA has now invoked its Business Continuity Plan (BCP) to allow the Agency to manage the pandemic. The plan aims to safeguard the Agency’s core activities and to ring-fence resources that are needed to deal with COVID-19.

Most EMA staff are now working remotely. Despite the reduction in the physical presence of staff at the Agency’s premises, the EMA’s core activities in relation to the authorization and supervision of medicines continue in phase 1 of the EMA COVID-19 BCP. In addition, the EMA’s scientific committees, working parties and certain stakeholder events will, for the time being, take place virtually until the end of April 2020.